Related Experiment Videos
Hypertrophic cardiomyopathy: presentation and pathophysiology
S Lerakis1, R G Sheahan, G A Stouffer
1Department of Medicine, University of Texas Medical Branch, Galveston 77555-1064, USA.
Insights
Hypertrophic cardiomyopathy (HCM) is complex, but genetic insights improve diagnosis and risk stratification for cardiovascular mortality. New treatments are emerging, requiring clinical trials for optimal patient care.
Area of Science:
- Cardiology
- Genetics
- Internal Medicine
Background:
- Hypertrophic cardiomyopathy (HCM) presents heterogeneously with diverse clinical manifestations.
- Understanding the genetic basis of ventricular hypertrophy is advancing diagnostic capabilities.
Observation:
- Genetic discoveries aid in identifying patient subgroups at high risk for cardiovascular mortality.
- Challenges persist in managing HCM symptoms and preventing sudden cardiac death (SCD).
Findings:
- Several novel therapeutic strategies for HCM are currently under investigation.
- New treatment options aim to improve symptom relief and reduce mortality risk.
Implications:
- Future randomized trials are essential to compare major HCM interventions.
- Evidence-based guidance is needed for optimal treatment strategies, including pharmacologic therapy and surgical/interventional procedures.
Abstract:
HCM is a heterogeneous disease with various clinical presentations. Recent advances in understanding the genetic abnormalities responsible for ventricular hypertrophy promise to improve our ability to diagnose this condition and to identify subgroups who are at the highest risk of cardiovascular mortality. Numerous difficulties remain in treating patients with HCM, including obtaining relief of symptoms and preventing SCD, but several new treatment options are currently being evaluated. In the future, randomized trials comparing the major treatment options (eg, pharmacologic therapy, myotomy/myectomy, mitral valve replacement, pacemaker implantation, and nonsurgical septal reduction) will be needed to provide guidance concerning the optimal treatment of patients with HCM.